The prognostic role of cell kinetics (expressed as 3H-thymidine labelling index, 3H-TdR LI) was assessed on 145 patients with pathologic stage II melanoma subjected only to therapeutic lymph node dissection. The 3H-TdR LI determined on metastatic nodes was related to relapse-free survival and to survival. In particular, 3-year relapse-free survival was significantly different from patients with slowly and rapidly proliferating melanomas (40% vs 22%, P=0.007), and this finding was consistently found for overall survival (68% vs 46%, P=0.007). Moreover, in patients with high 3H-TdR LI tumours, the risk of relapse and death within the first year from lymphadenectomy was two-fold that of patients with low 3H-TdR LI tumours. Multiple regression analysis showed that 3H-TdR LI retained its prognostic significance on relapse-free and on overall survival even when the number of involved nodes and type of nodal metastases were considered. Present findings suggest that 3H-TdR LI can contribute to select high-risk stage II melanoma patients.
Prognosis in patients with stage II melanoma is related to features of the primary tumour and of nodal metastases (Balch et al., 1981; Cascinelli et al., 1984; Roses et al., 1985; Koh et al., 1986; Kissin et al., 1987) . Survival is inversely related to the number of positive nodes and also decreases when perilymph node invasion is present (Balch et al., 1981; Rayner et al., 1981; Callery et al., 1982; Cascinelli et al., 1984) . However, it has also been emphasised that nodal metastases are indicators, not determinants of survival in pathologic stage II melanoma patients (Cady, 1984) . Cell kinetics, studied by different approaches, has emerged as an important indicator of biologic aggressiveness (Bauer et al., 1987; Kallioniemi et al., 1987; Quirke et al., 1987; Griffin et al., 1988; Hall et al., 1988; Bouzubar et al., 1989) . In particular, the 3H-thymidine labelling index (3H-TdR LI) has been shown to be a prognostic factor whose role remains also in the presence of other clinico-pathologic prognostic factors (Meyer et al., 1983; Silvestrini et al., 1986 Silvestrini et al., , 1989 Chauvel et al., 1988) .
Little attention has been given to cell kinetics in malignant melanoma (Shirakawa et al., 1970; Hagemann & Schiffer, 1971; Newburger et al., 1980; Hansson et al., 1982; Costa et al., 1987) . The data available on preliminary series of stage II melanoma patients strongly indicate the potential clinical usefulness of cell kinetics as a prognostic marker (Hansson et al., 1982; Costa et al., 1987) . However, the relative contribution of cell kinetics in relation to information given by other morphologic and pathologic features has been never analysed.
In this follow-up study, we report on a group of 166 patients with pathologic stage II melanoma of the skin to substantiate, in a larger series with a longer follow-up, our preliminary findings. However, we investigated the possible association of cell kinetics with established clinico-pathologic parameters and we estimated the different contribution of all the variables on the clinical course, in terms of relapse-free interval and overall survival, by means of a multiple regression analysis.
The main basic limitation in starting the study was the impossibility to perform the cell kinetics determination on the primary tumour, which is completely reserved for the pathologist for Clark's (1969) and Breslow's (1970) Cell kinetic determination Cell kinetics was defined as in vitro 3H-TdR LI on fresh pathologic lymph nodes immediately after dissection, as previously described (Costa et al., 1987) . Briefly, small fragments were incubated with 3H-thymidine (6 jlCi ml1 ', specific activity, 5 Ci mmol '; Radiochemical Centre, Amersham, UK) in culture medium for 1 h at 37°C. Autoradiography was performed on histologic sections according to the stripping film technique (Kodak AR10, Kodak, London, UK), and the samples were stained with haematoxylin and eosin. The 3H-TdR LI was determined by scoring at least 3,000 tumour cells per sample. The determination of 3H-TdR LI on the sections from different samples of the same tumour showed a median coefficient of variation of 25%.
Statistical methods
Comparison of the 3H-TdR LI values among the different subsets identified by the various prognostic factors was done by the Wilcoxon rank sum test. The Bonferroni procedure was adopted to allow for multiple comparisons. The two major end-points, relapse-free survival (RFS) and overall survival, were computed from the time of node dissection until clinically evaluated relapse or death on 145 patients with an adequate follow-up. The observation times ranged from 1 to 75 months, and the median follow-up was 25 months. First of all, a univariate analysis was carried out to estimate RFS and survival curves relative to the different modalities of each prognostic variable by means of the Kaplan-Meier product-limit method (Kaplan & Meier, 1958) . Comparisons among curves were accomplished by resorting to the log rank test (Mantel, 1966) . The hazard function was estimated according to the approach proposed by Simes and Zelen (1985) . Six-month intervals were chosen to calculate the hazard estimates.
The joint effect of the variables, possibly influencing prognosis, was investigated by a Cox's multiple regression model (Cox, 1972) .
The role of 3H-TdR LI was investigated after classifying tumours in two classes with different proliferative rates. the value of 8%, which represents the mean value of the distribution of this variable, was used to discriminate slowly and rapidly proliferating melanomas. Other cut-off levels were tested by means of the Kaplan-Meier product-limit method, and the log rank test was used to assess differences in RFS and survival between subgroups. x2 values with one degree of freedom were calculated with the corresponding P values, and the highest x2 value was observed at a 3H-TdR LI cut-off of 8%.
Results
3H-TdR LI values defined for the overall series of 166 nodal lesions were highly skewed, with a mean value of 8.6% and a range from 0.3 to 31%, in agreement with our previous results (Costa et al., 1987) . Cell kinetics was analysed in relation to the clinico-pathological features considered prognostic factors in stage II melanoma patients (Table I) . 3H-TdR LI was not related to age or sex of the patient, to number of positive nodes, or to type of metastases.
The overall 3-year RFS and survival for the series of 145 patients, for whom cell kinetic and follow-up information was available, were 32% and 59%, respectively. This finding is in agreement with other clinical reports on larger series of stage II melanoma patients (Balch et al., 1981; Cascinelli et al., 1984; Kissin et al., 1987) . The analysis as a function of 3H-TdR LI showed significant differences in the probability of RFS between patients with slowly and rapidly proliferating tumours (40% vs 22%, P = 0.007) (Figure la) . The survival curves were also significantly different (68% vs 46%, P = 0.007) (Figure lb) . Relapse and death hazard over time showed similar patterns for the two kinetics subsets of patients (Figure 2) , with a peak of risk from 6 to 12 months from lymphadenectomy. The hazard was higher for patients with rapidly proliferating tumours than for those with slowly proliferating tumours for the whole follow-up period.
Univariate analysis of 3-year RFS and survival as a function of number of positive nodes and type of nodal invasion was performed on the two subsets with less or more than two positive nodes owing to the unbalanced number of cases within the different categories. Patients with partial or massive nodal involvement were considered together. When Figure 2 Estimated hazard function of relapse and death (per 100 persons per 6 months) for patients with slowly (---) and rapidly (-) proliferating tumours.
VE IE I nI singly tested, number of positive nodes was associated to clinical outcome. Patients with <, 2 N + showed a higher probability of RFS (43% vs 13%, P = 0.0004) and survival (66% vs 46%, P = 0.04) than patients with >2 N + ( Figure  3a,b) . Moreover, the probability of RFS at 3 years was significantly lower for patients with extracapsular diffusion of disease (27%) than for patients with intracapsular disease (44%; P = 0.03) (Figure 4a ). Within the latter group, a different RFS was observed for patients with partial or massive nodal involvement. No statistically significant difference was observed among the corresponding survival curves. (Figure 4b ). Age and sex of patients did not affect RFS or survival.
Multiple regression analysis was carried out to evaluate the joint effect of prognostic factors on RFS and survival. Age and sex were excluded from the evaluation because, by single factor analysis, they were clearly not associated with RFS and survival. The 3H-TdR LI was added to the regression models including the two pathologic variables, i.e. number of positive nodes and type of nodal invasion (Table II) (Balch et al., 1981; Rayner et al., 1981; Callery et al., 1982; Cascinelli et al., 1984) . This finding has been confirmed in the present series of patients: 3-year RFS and survival were significantly lower for patients with more than two positive nodes and massive invasion, regardless of diffusion beyond the capsule. As observed for other human tumours (Meyer et al., 1983; Tubiana et al., 1984; Silvestrini et al., 1986 Silvestrini et al., , 1989a Chauvel et al., 1988) , cell kinetics varies widely from patient to patient, and there is no evident relationship between 3H-TdR LI of metastatic lesions and clinico-pathologic features considered to be prognostic factors in stage II melanoma patients.
The present study confirms the previous finding on the value of cell kinetics as a prognostic factor in stage II melanoma patients subjected to nodal dissection (Hansson et al., 1982;  Costa et al., 1987) , even after making allowance for all the other known prognostic factors. In fact, multiple regression analysis showed that 3H-TdR LI retained its importance as an indicator of RFS and became the most important indicator of survival even in the presence of number of involved nodes and type of nodal metastases, at least for the first 3 years after surgery. Our findings, which reproduce those reported for other tumour types (Meyer et al., 1983; Tubiana et al., 1984; Silvestrini et al., 1986 Silvestrini et al., , 1989a Chauvel et al., 1988) , indicate that, even for stage II melanoma patients, cell kinetics should improve the assessment of prognosis.
